GlassScriptPhysician profile
John F Vela
NPI 1548267685
$1,478.77
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $364 · 2021: $510.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $408.30 | 2019-2021 | |
| Amgen INC. | $201.05 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $170.64 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $162.72 | 2019-2021 | |
| Amarin Pharma, INC. | $95.50 | 2019-2021 | |
| Pfizer INC. | $89.12 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $77.63 | 2021 | |
| Kaleo, INC. | $65.75 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $54.22 | 2019 | |
| Bardy Diagnostics, INC. | $30.00 | 2019 | |
| Abbvie INC. | $27.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.73 | 2019-2020 | |
| Sanofi Pasteur INC. | $13.06 | 2020 | |
| Optinose US, INC. | $12.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.23 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $12.14 | 2021 | |
| Merck Sharp & Dohme LLC | $11.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.07 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.